Abstract
Oxaliplatin (OXA) is a valuable and largely used cancer drug which induces a serious and intractable neuropathy. The lipoyl-homotaurine derivative (ADM_12) reverts in vivo OXA-induced neuropathy, and it is an effective antagonist of the nociceptive sensor channel TRPA1. Unprecedentedly, this safe analgesic showed a synergy with OXA in vitro and proved to inhibit CA IX, a relevant therapeutic target, clearly interfering with pancreatic cancer cells' aggressiveness.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / toxicity
-
Carbonic Anhydrase IX / antagonists & inhibitors*
-
Carbonic Anhydrase Inhibitors / pharmacology
-
Cell Line, Tumor
-
Drug Synergism
-
Humans
-
Neoplasms / complications
-
Neoplasms / drug therapy*
-
Neoplasms / pathology
-
Organoplatinum Compounds / therapeutic use
-
Organoplatinum Compounds / toxicity*
-
Oxaliplatin
-
Pancreatic Neoplasms / drug therapy
-
Pancreatic Neoplasms / pathology
-
Peripheral Nervous System Diseases / chemically induced
-
Peripheral Nervous System Diseases / drug therapy*
-
TRPA1 Cation Channel / antagonists & inhibitors
-
Taurine / analogs & derivatives*
-
Taurine / chemistry
-
Taurine / pharmacology
Substances
-
Antineoplastic Agents
-
Carbonic Anhydrase Inhibitors
-
Organoplatinum Compounds
-
TRPA1 Cation Channel
-
TRPA1 protein, human
-
Oxaliplatin
-
Taurine
-
tramiprosate
-
Carbonic Anhydrase IX